Meeting
2020 ASCO Virtual Scientific Program
TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors.
Authors
Ashish Saxena
Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY
Ashish Saxena , Loren S. Michel , Quan Hong , Karrie Hilsinger , Charu Kanwal , Cabilia Pichardo , Trishna Goswami , Alessandro Santin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Immunoconjugates (non-IO)
Clinical Trial Registration Number
NCT03964727
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS3648)
DOI
10.1200/JCO.2020.38.15_suppl.TPS3648
Abstract #
TPS3648
Poster Bd #
378
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
TROPiCS-03: A phase 2 basket study of sacituzumab govitecan (SG) in patients (pts) with metastatic solid tumors—Early analysis in pts with advanced/metastatic endometrial cancer (EC).
First Author: Alessandro Santin
Poster
2021 ASCO Annual Meeting
Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1– metastatic triple-negative breast cancer (mTNBC).
First Author: Ana Christina Garrido-Castro
Poster
2020 ASCO Virtual Scientific Program
Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase I/II study.
First Author: Alessandro Santin
Poster
2020 ASCO Virtual Scientific Program
EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors.
First Author: Justine Yang Bruce